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We identiﬁed a major peptide signaling target of EGF/EGFR pathway and explored the consequences of blocking or activating
this pathway in the ﬁrst trimester extravillous trophoblast cells, HTR-8/SVneo. A global analysis of protein phosphorylation
was undertaken using novel technology (Kinexus Kinetworks) that utilizes SDS-polyacrylamide minigel electrophoresis and
multi-lane immunoblotting to permit speciﬁc and semiquantitative detection of multiple phosphoproteins. Forty-seven protein
phosphorylation sites were queried, and the results reported based on relative phosphorylation at each site. EGF- and Iressa-
(geﬁtinib, ZD1839, an inhibitor of EGFR) treated HTR-8/SVneo cells were subjected to immunoblotting and ﬂow cytometry to
conﬁrm the phosphoprotein screen and to assess the eﬀects of EGF versus Iressa on cell cycle and apoptosis. EGFR mediates
the phosphorylation of important signaling proteins, including PKBα/AKT. This pathway is likely to be central to EGFR-
mediated trophoblast survival. Furthermore, EGF treatment induces proliferation and inhibits apoptosis, while Iressa induces
apoptosis.
1.Introduction
Epidermal growth factor (EGF) and its receptor (EGFR) are
known to play critical roles in cell growth, diﬀerentiation,
angiogenesis, and inhibition of apoptosis. EGF is a multi-
functional 53 amino-acid peptide known for its ability to
stimulate proliferation and diﬀerentiation in the placenta as
well as many other cells and tissues [1]. EGF is important
in embryonal implantation and trophoblast diﬀerentiation;
itiscriticalfornormalplacentalendocrinefunction[2].EGF
and its membrane-bound receptor, EGFR, are expressed in
the placenta and can be found at all stages of diﬀerentiation;
however, the signaling events activated by this pathway
in the trophoblast are not fully understood. Nevertheless,
growth factors such as EGF are believed to be intimately
involved with the control of trophoblast physiology, and
abnormal levels of EGFR have been reported in the pla-
centa from pregnancies complicated by intrauterine growth
restriction (IUGR), preeclampsia, and diabetes mellitus [3].
The association of EGF/EGFR with normal and aberrant2 Obstetrics and Gynecology International
placental function makes the study of downstream signaling
pathways activated by this growth factor an important area
of investigation.
EGFR signals through a series of protein kinases. These
are important transducers of information in human cells
with the ability to regulate cellular functions by catalyzing
the direct phosphorylation of target proteins [4]. Protein
kinasesoperatewithincomplexsystemsoffunctionallyinter-
connected signaling protein networks. Identiﬁcation of the
principal EGFR-mediated signaling pathway in trophoblast
cells would allow a more complete understanding of the
eﬀects of EGF on placental physiology and development.
However, to understand EGFR signaling at the global
level, it is crucial to track the phosphorylation and the
activation of multiple potential protein kinase targets in
a reliable, semiquantitative, and accurate manner. In these
experiments,weusedphosphoproteinproﬁlingwithKinexus
technology to identify EGFR targets in HTR-8/SVneo cells.
Phosphorylation at 47 sites on 31 potential targets was
queried using cells treated with EGF and/or Iressa (geﬁtinib,
ZD1839), a speciﬁc blocker of EGFR phosphorylation. Sites
were identiﬁed for which phosphorylation was induced by
EGF and/or inhibited by Iressa. The downstream eﬀects of
signaling through the identiﬁed pathways were investigated
using cell growth and apoptotic assays [5].
2.MaterialandMethods
2.1. Cell Culture and Treatment. Transformed human tro-
phoblast-8 (HTR-8/SVneo) cells, originally obtained from
Professor Charles Graham (Toronto, Canada), were grown
to approximately 80% conﬂuence in minimum essential
medium (Invitrogen Corporation, Carlsbad, Calif, USA)
with 50mL of fetal bovine serum (Invitrogen, Carlsbad,
Calif, USA) [6]. The cells were subsequently serum-starved
for 24h and divided into four groups: control (vehicle
alone),EGF(30ng/mL,Invitrogen,Carlsbad, Calif,USA)for
5min, Iressa (1μM, Astra-Zeneca Pharmaceuticals, London,
England) for 20h, and Iressa plus EGF. Iressa was dissolved
in DMSO and EGF was dissolved in distilled water according
to the manufacturer’s protocol. Controls were performed to
ensure the absence of eﬀects with the respective vehicles.
2.2. Protein Extraction. Cells were harvested and washed
twice with PBS. Protein lysate was obtained according to
Kinetworks’ guidelines (Kinexus, Victoria, BC). Brieﬂy,
protein was extracted using 0.5% Triton X-100 lysis buﬀer
with sonication for 10 seconds on ice to rupture the cells.
Cell extracts were then ultra-centrifuged for 30min at
100,000×g. The supernatant was transferred to fresh tubes,
and protein concentrations were assayed promptly using
Bradford dye and a microplate reader according to the
manufacturer’s protocol (BioRad, Hercules, Calif, USA).
For each sample, 400μg of protein was transferred to a
fresh 1.5mL Eppendorf screw cap vial and mixed with 4x
sample buﬀer (125mM Tris-HCl pH 6.8, 4% w/v SDS,
50% v/v glycerol, 0.08% w/v bromophenol blue, and 5% β-
mercaptoethanol) in a ratio of 1:4 sample to buﬀer. Samples
were then boiled for 4min, placed in tightly locked tubes
and shipped to Kinexus, Inc. for quantiﬁcation.
2.3. Multipeptide Immunoblotting. Multipeptide immuno-
blotting was performed according to the manufacturer’s in-
structions using Kinetworks Phospho-Site Screen 1.3
(Kinexus, Victoria, BC), which tracks the abundance of
the following phosphoprotein targets: Adducin A (S724),
Adducin G (S662), CDK1 (Y15), CREB (S133), ERK1
(T202/Y204), ERK2 (T185/Y187), GSK3-alpha (S21, Y279),
GSK3-beta (S9, Y216), JUN(S73), JNK/SAPK (T183/Y185),
MEK1/2 (S217/S221), MEK3/6 (S189/S207), MSK1 (S376),
NR1 (S896), p38-alpha MAP kinase (T180/Y182), S6K
p70 (T389), PKB-alpha/AKT (S473/T308), PKC-alpha
(S657), PKC-alpha/beta (T638/641), PKC-delta (T507),
PKC-epsilon (S729), PKR (T451), RAF1 (S259), RB1 (S780,
S807/811), RSK1 (T359/S365), JNK/SAPK (T183/Y185),
SMAD1 (S463/465), SRC (Y418/Y529), STAT1 (Y701),
STAT3 (S727), and STAT5 (Y694). By this method, 47
phosphosites on 31 proteins are identiﬁed.
Phosphorylation of each target was assessed using 300μg
of total protein extract resolved on a 13% single-lane SDS-
polyacrylamide gel and transferred to a nitrocellulose mem-
brane. Using a 20-lane multiblotter from BioRad (Hercules,
Calif, USA), the membrane was incubated with diﬀerent
mixtures of up to three antibodies per lane that react with
a distinct subset of phosphorylated cell signaling proteins
of known molecular masses, as listed above. After further
incubation with a mixture of relevant HRP-conjugated
secondary antibodies (Santa Cruz Biotechnology, Santa
Cruz, Calif, USA), the blots were developed using ECL Plus
reagent (Amersham Pharmacia, Piscataway, NJ, USA), and
the signals were quantiﬁed using Quantity One software
(BioRad) [7]. The relative density of each phosphoprotein
band was determined by comparison with the control
cells. The results were reported as the percent of binding
compared to the control. Peptide densities that varied ±25%
or more and were consistently present were considered to
be legitimate targets of EGF/EGFR signaling, which could be
reliably detected using this method.
2.4. Western Blotting. Conﬁrmation of the multilane
immunoblotting data with respect to the principal target
identiﬁed, PKBα/AKT, was performed by standard Western
blotting. The antibody for PKBα/AKT was speciﬁc to the
S473 site (Novus, Littleton, Colo, USA). Immunoblotting
was also performed for PARP-1, a marker for apoptosis, and
for total EGFR (Santa Cruz Biotechnology, Santa Cruz, Calif,
USA). HTR-8/SVneo cells were plated in 150mm dishes and
were grown for 24h and then serum starved. The treatments
were control (with DMSO as the vehicle), EGF (30ng/mL
in DMSO) for 5min, Iressa only (1μMi nD M S O )f o r2 0h ,
and Iressa for 20h + EGF for 5min. After treatment, cells
were harvested and centrifuged for 2min at 500×g. Cell
pellets for each treatment were lysed with extraction buﬀer
[1% (v/v) Triton X-100, 10mM Tris-HCl pH 7.4, 5mM
EDTA, 50mMNaCl, 50mM NaF, 20μg/mL Aprotinin,
1mMPMSF , and 2mMN a 3VO4]a sp r e v i o u s l yd e s c r i b e dObstetrics and Gynecology International 3
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6: JNK (SAPK)
7: PKCa/b
8: MEK3/6
9: p 70 s6k
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(c) HTR-8 Treated with Iressa
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Figure 1: (a) Kinexus multilane immunoblot showing untreated HTR-8/SVneo cells (control). (b) Kinexus multilane immunoblot showing
HTR-8/SVneo cells treated for 5min-with EGF (30ng/mL). Thirty-one phosphorylated proteins were tracked. Twenty-four proteins (see
Table 1) were phosphorylated in HTR-8/SV neo cells. Seven of the proteins were not phosphorylated. PKBα/AKT is a principal target which
is phosphorylated by EGF (see immunoblot band marked 16). (c) Kinexus multilane immunoblot showing HTR-8/SVneo cells treated
for 20h with Iressa (1μM) plus EGF (30ng/mL) for 5min. Phosphorylation of PKBα/AKT was downregulated in the presence of Iressa
(immunoblot band marked by 16). (d) Kinexus multilane immunoblot showing HTR-8/SVneo cells treated for 20h with Iressa (1μM).
Phosphorylation of PKBα/AKT is signiﬁcantly downregulated (see band marked by 16). (e) This graph represents the fold induction or
downregulation of pKBα/AKT in response to EGF, Iressa, EGF + Iressa normalized to baseline untreated cells.4 Obstetrics and Gynecology International
by Lange, et al. [8, 9] and subjected to three freeze/thaw
cycles. The lysate was cleared by centrifugation at 20,000×g
for 10min. The protein concentration of the whole cell
lysates was determined by the Bradford method (BioRad,
Hercules, Calif, USA). Equal amounts of protein (100μg)
for each treatment were separated by 7.5% SDS-PAGE.
Proteins were transferred onto a nitrocellulose membrane
(BioScience, Dassel, Germany) and the membrane was then
probed with a primary antibody against phospho-AKT
(S473), total EGFR, or PARP-1 followed by incubation
with an HRP-conjugated secondary antibody. The signal
was visualized by chemiluminescence using ECL Western
blotting detection reagents (Pierce, Rockford, Il, USA). Actin
was used as a loading control.
2.5. Flow Cytometry. To determine the eﬀects of EGF
treatment and/or Iressa blockade on cell cycle and apoptosis,
cells were grown to 80% conﬂuence and treated as described
above. Cells were then harvested by scraping, washed 3x
with PBS, and stained with Krishan’s solution (NA citrate
2H2O, propidium iodide, 1% NP40, and 10mg/mL RNAse
A). Stained cells were analyzed on a FACS Calibur ﬂow
cytometer using CellQuest software version 3.3 (both Becton
Dickinson, San Jose, Calif, USA). Data analysis was per-
formed using FlowJo software version 6.4 (Tree Star, Inc.,
Ashland, Ore, USA). Cells were triggered on forward scatter,
gated by forward versus side scatter to exclude debris, and
then gated on PI ﬂuorescence area versus width to eliminate
doublets. PI area was used to determine the percentage of
cells in each compartment of the cell cycle. The proportion
of the cells in the sub-G1 compartment was used as a relative
indicator for apoptosis.
2.6. Apoptosis Assay. To further conﬁrm the eﬀect of Iressa
treatment to block EGF/EGFR signaling on programmed cell
death, cells were stained, and the cells undergoing apop-
tosis were counted. Hoechst 33342 dye (Molecular Probes,
Eugene, Ore, USA) was used for these studies, because it
provides a rapid ﬂuorescence assay to detect condensed
chromatin in apoptotic cells. This blue ﬂuorescent dye stains
chromatin at an excitation/emission wavelength of 340–
461nm when bound to DNA. The chromatin of apoptotic
cells stains more brightly than the chromatin of normal cells.
HTR-8/SVneo cells were seeded in 6-well plates with 3mL of
complete medium added to each well. Cells were grown to
80% conﬂuence in complete media, serum-depleted media,
serum-depleted media + EGF (as above), or serum-depleted
media + 1μM Iressa. Twenty hours later, the media was
removed and Hoechst dye was added to each well for 30min.
Cells were assessed for apoptotic features using a confocal
microscope (Olympus FluoView 1000, Melville, NY, USA).
The main morphological characteristics assessed were cellu-
lar and nuclear shrinkage (pyknosis), nuclear fragmentation
(karyorrhexis), chromatin condensation, blebbing, and the
formation of apoptotic bodies [10]. The apoptotic cells were
counted in four randomly selected ﬁelds by an investigator
blinded to the treatment group. The percentage of cells
undergoing apoptosis was calculated.
pAKT (Ser473)
β-actin
123 4
Cleaved PARP
EGFR
Figure 2: Immunoblot for PKBα/AKT, cleaved PARP, and EGFR.
HTR-8/SV neo cell treatments are as follows: Lane (1) serum-
starved control, (2) with EGF (30ng/mL, 5min), (3) Iressa (1μM,
20h), and (4) EGF (30ng/mL, 5min) + Iressa (1μM, 20h).
3. Results and Discussion
Using Kinetworks Phospho-Site Screen 1.3, tracking the 47
phosphorylation targets speciﬁed in the methods, multiple
diﬀerences were noted in the phosphoprotein proﬁle of each
treatment group using the cutoﬀ of at least 25% diﬀerence
between treatments. Compared to controls, EGF treated
cells demonstrated the upregulation of 12 phosphoproteins
[Adducinα, CREB, ERK2, Jun, MSK1/2, p38 MAPK, p70
S6K, PKBα/AKT (S473 and T308), PKCα,R B ,S R Ca n d
STAT5], whereas ﬁve target phosphoproteins [CDK1, NR1,
RAF1, SAPK, and MEK3/6] were downregulated. For cells
treated with Iressa alone, six phosphoproteins [CREB,
GSK3β,J U N ,P K C α,P K C α/β, and RB] were upregulated
and 11 phosphoproteins [Adducin g, CDK1, ERK1, ERK2,
MEK1/2, NR1, p38 MAPK, PKBα/AKT (S473 and T308),
PKCe, RAF1, and SAPK] were downregulated. Representa-
tive blots of cells grown under control conditions, compared
to cells treated with EGF, Iressa, and EGF + Iressa are shown
in Figures 1(a)–1(d). The counts per minute (CPM) for
each phosphorylation site under each condition is shown in
Table 1.
We reasoned that the principal EGFR phosphorylation
target(s) would be both robustly induced by EGF and
strongly downregulated by Iressa. Protein Kinase B-α/AKT
consistently met these criteria, both at S473 and T308.
Phosphorylation at S473 is shown in bar graph format in
Figure 1(e). Phosphorylation of S473 was induced 328%
by EGF compared to control cells and reduced to baseline
with the addition of Iressa. Phosphorylation at T308 was
also increased over baseline, but the exact percentage could
not be calculated, because the baseline phosphorylation
at this site in control cells was undetectable. Addition of
EGF strongly enhanced phosphorylation at T308, and Iressa
inhibited phosphorylation back down to undetectable levels.
Conﬁrmation of the Kinexus data was performed by Western
blottingandisrepresentedinFigure 2,showingupregulationObstetrics and Gynecology International 5
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Figure 3: Flow cytometric analysis of cell cycle in response to EGF and Iressa. The sub-G1 fraction consists of a high proportion of apoptotic
cells.
of phospho-PKBα/AKT S473 with EGF treatment but down-
regulation with Iressa alone or Iressa + EGF.
Proteins that were phosphorylated in HTR-8/SVneo cells
butnotsigniﬁcantlyaﬀectedbyEGFRactivationorblockade,
include the following: Adducin a, Adducin g, CDK1, CREB,
ERK1, ERK2, GSK3a, GSK3b, JUN, MEK1/2, MEK3/6,
MSK1/2, NR1, PKCa, PKCa/b, PKCe, RAF1, SAPK, SRC,
and STAT1 (Table 1). These sites represent pathways that are
presumably signaling, but are not under the control of EGFR
under the conditions tested. Proteins that were not phos-
phorylated in HTR-8/SVneo cells include: MEK6, PKCd,
PKR, RSK1, SMAD1, SRC, and STAT3. These sites represent
downstream signaling targets that are not activated. Hence,
these data indicate that of the 47-phosphorylation sites on
31proteinsqueriedandundertheconditionsspeciﬁed,some
sites were clearly regulated through EGFR (the major one
being PKBα/AKT), and some were not. Other sites were
phosphorylated but were not inﬂuenced by EGFR activation
or inhibition.
Flow cytometry was employed to assess the eﬀects of
EGF +/− Iressa and Iressa alone on the cell cycle (Figures
3(a)–3(d)). Compared to control cells grown without serum,
EGFtreatmentinducedanincreaseintheproliferativephases
of the cell cycle, G1 and S, by 2.5% and 1.9%, respectively,
a meaningful result keeping in mind that over time, this
will result in many more cells going through the cycle. On
the other hand, Iressa treatment in the presence of EGF
reduced the percentage of cells in G1 and S by 3% and 2.8%,
respectively, and increased the percent of cells in the sub-G1
phase by 10%. This indicates that Iressa is able to block the
proliferativeeﬀectsofEGFandtoenhancecellularapoptosis.
Similarly, PARP-1 cleavage, a marker for apoptosis, was
induced with Iressa treatment, further conﬁrming the induc-
tion of programmed cell death through this pathway. Total
EGFRlevelswereunchangedbyEGFand/orIressatreatment,
as shown in Figure 2, indicating that modulation of EGFR
(an increase or decrease in expression) is not the reason for
altered cell growth and apoptosis in our experiments.
The eﬀects of Iressa on apoptosis were studied further
using ﬂuorescence microscopy in the presence of Hoechst
dye, as shown in Figure 4. Only 2% of cells were apoptotic
when grown in complete media with serum. Depletion
o fs e r u mr e s u l t e di na ni n c r e a s ei na p o p t o s i st o1 2 % ,
and the further addition of 1μM Iressa enhanced cellular
apoptosis to 16.5% (Figure 4(d)). Using the Student’s t-test,
signiﬁcantly more cells were apoptotic in serum-depleted
media compared to control conditions in which cells were
grown in complete media (P< 0.0001). Addition of Iressa
to serum-depleted media resulted in a further signiﬁcant
increase in the percent of apoptotic cells (P = 0.038).
EGF was able to partially inhibit apoptosis compared to
serum depletion although this eﬀect did not reach statistical
signiﬁcance in this assay and is thus not shown. The eﬀect of
Iressa on cell viability conﬁrmed the apoptotic assays, where
treatment resulted in a 31% decrease in HTR-8 cell viability
compared to the serum-starved condition (data not shown).6 Obstetrics and Gynecology International
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Figure 4: Apoptosis in response to Iressa and serum starvation. HTR-8/SVneo cells as visualized by an Olympus laser confocal microscope
at 1000x. (a) HTR-8/SVneo cells grown in complete media, (b) HTR-8/SVneo cells grown in serum-starved media for 24h, and (c) HTR-
8/SVneocells were growninserum-starvedmedia withIressa(1μM). Graph (d) represents theaverage percent of apoptotic cells in complete
media (a), serum-starved media (b), Iressa + complete media (picture not shown), and Iressa in serum-depleted media (c). Error bars =
standard error of the mean.
4. Conclusions
T h el i t e r a t u r es t r o n g l ys u p p o r t sap r i m a r yr o l ef o rE G F R
signaling in the development and the function of the
trophoblast [11]. The EGF pathway is central to the control
of trophoblast invasion and the inhibition of apoptosis [12,
13]. The purpose of this study was to identify the principal
EGFR signaling pathways in ﬁrst trimester trophoblast cells
and to conﬁrm the biological signiﬁcance of these ﬁndings
on the induction of programmed cell death. Iressa is known
to be a potent oral speciﬁc inhibitor of EGFR tyrosine kinase
activity and competes for its binding site with adenosine
triphosphate on the intracellular domain of the receptor
[14].Itwasusedinthisstudy,alongwithEGF,toassesswhich
pathways were clearly under EGFR control (induced by EGF
and blocked by Iressa) in our cell model.
This study utilized a novel technology to analyze protein
expression and phosphorylation changes in 31 proteins. The
pathways queried are illustrated in Figure 5. However, this
technologyhaslimitations.Itisahigh-throughputtechnique
but requires conﬁrmation by standard protein assays such
as Western blotting, as shown in Figure 2. In addition, the
biological signiﬁcance of the changes in protein phosphory-
lation should be veriﬁed, as we have done in these studies.
The principal EGFR target reproducibly induced by EGF
and inhibited by Iressa was PKBα/AKT. Two sites on this
protein, S473 and T308, were controlled by EGFR signaling.
PKBα/AKT phosphorylation occurs through phosphatidyli-
nositol 3 kinases. Full activation of PKBα/AKT requires
phosphorylationatbothS473andT308.Thesesitesareinde-
pendently phosphorylated by two intermediates, PI(3,4,5)P3
and PI(3,4)P2, respectively [15]. Interestingly, EGF induced
and Iressa blocked both sites, indicating that EGFR sig-
naling results in robust activation of PKB. In response to
S473 and T308 phosphorylation, PKBα/AKT modulates the
phosphorylation of over 40 diﬀerent downstream peptides.
PKBα/AKT is involved in the regulation of many biological
processes, including cell proliferation, growth, apoptosis,Obstetrics and Gynecology International 7
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Figure 5: EGF activated pathways in HTR-8sv/neo cells. EGF can
signal through multiple pathways and ultimately inﬂuence many
diﬀerent downstream peptides. A major eﬀect identiﬁed in these
studies is through modulation of PKBα/AKT (bold).
and tumorigenesis, as shown in Figure 5.P K B α/AKT is
particularly well known as a negative regulator of apoptosis
[16].PhosphorylationofPKBα/AKTinhibitsJNKactivation,
leading to the inability to activate the cellular signaling scaf-
fold required to induce apoptosis (17). PKBα/AKT has also
been implicated in nitric oxide regulation, glucose home-
ostasis, and insulin signaling [16–18]. Studies have shown
that reduction in the phosphorylation of PKBα/AKT and
the consequences on downstream signaling molecules may
have detrimental eﬀects on newborn pregnant mice. Gene
disruption of PKBα/AKT results in placental insuﬃciency,
fetal growth impairment, and death in the newborn [19].
In summary, these studies indicate that EGF signaling
through EGFR activates PKBα/AKT as a principal target,
and blocking this pathway with the EGFR-speciﬁc tyrosine
kinase inhibitor, Iressa, results in programmed cell death.
We hypothesize that blocking EGFR signaling may result in
apoptosis via inhibition of PKBα/AKT. Loss or deactivation
of PKBα/AKT, as suggested by gene disruption models, may
be linked to the pathogenesis of IUGR. Further studies are
planned to determine whether IUGR in human pregnancies
Table 1: Kinexus quantitation of phosphosites in response to Iressa
and EGF. Table shows counts/minute/ at each phosphorylation site
in control cells compared to EGF, EGF + Iressa-treated cells, and
Iressa.Thesedataarethequantitativeresultsfromtheimmunoblots
in Figure 1.
Phosphoprotein Control
CPM
EGF
CPM
Iressa + EGF
CPM
Iressa
CPM
Adducin a 2525.76 3230.00 2152.00 2589.00
Adducin g 1661.92 1457.00 1969.00 596.00
CDK1 4850.79 3184.00 4417.00 3311.00
CREB 412.29 525.00 1138.00 535.00
ERK1 1620.04 1394.00 1186.00 179.00
ERK2 1051.38 1175.00 913.00 186.00
GSK3a 186.75 189.00 147.00 165.00
GSK3a 3476.29 3194.00 1829.00 3144.00
GSK3b 2330.41 2620.00 2381.00 3279.00
GSK3b
JUN 289.71 432.00 612.00 801.00
MEK1/2 538.75 522.00 460.00 136.00
MEK3/6 3114.65 2480.00 2341.00 3078.00
MEK6
MSK1/2
MSK1/2 284.33 378.00 271.00 337.00
NR1 752.75 351.00 399.00 196.00
p38 MAPK 2201.98 5045.00 2331.00 437.00
p70 S6K 248.00
p70 S6K 859.82 1218.00 777.00 866.00
PKBa (S473) 441.27 1887.00 243.00 326.00
PKBa (T308) 415.00
PKCa 9767.38 12176.00 14306.00 14817.00
PKCa/b 4652.87 5744.00 8439.00 8680.00
PKCd
PKCe 1533.96 1475.00 1151.00 1382.00
PKR
RAF1 2223.67 1443.00 1289.00 1307.00
RAF1 5897.68 4372.00 4195.00 3547.00
RB 795.37 1314.00 411.00 1116.00
RSK1
SAPK 285.45 153.00 179.00 145.00
SMAD1
SRC
STAT1 3071.94 3942.00 6013.00 3613.00
STAT3
STAT5 10297.67 14160.00 11465.00 10810.00
is linked to enhanced trophoblast apoptosis in response to
the dephosphorylation of PKBα/AKT downstream of EGFR.
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